


<OAI-PMH xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
         xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
    <responseDate>2025-09-09T13:52:12Z</responseDate>
    <request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:12407842" metadataPrefix="pmc">https://pmc.ncbi.nlm.nih.gov/api/oai/v1/mh/</request>
    
    <GetRecord>
        <record>
    <header>
    <identifier>oai:pubmedcentral.nih.gov:12407842</identifier>
    <datestamp>2025-09-04</datestamp>
    
        
        <setSpec>futoncol</setSpec>
        
    
        
        <setSpec>pmc-open</setSpec>
        
    
</header>
    <metadata>
        
        <article xmlns="https://jats.nlm.nih.gov/ns/archiving/1.4/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.4/ https://jats.nlm.nih.gov/archiving/1.4/xsd/JATS-archivearticle1-4.xsd" xml:lang="en" article-type="research-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Future Oncol</journal-id><journal-id journal-id-type="iso-abbrev">Future Oncol</journal-id><journal-id journal-id-type="pmc-domain-id">3069</journal-id><journal-id journal-id-type="pmc-domain">futoncol</journal-id><journal-title-group><journal-title>Future Oncology</journal-title></journal-title-group><issn pub-type="ppub">1479-6694</issn><issn pub-type="epub">1744-8301</issn><publisher><publisher-name>Taylor &amp; Francis</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12407842</article-id><article-id pub-id-type="pmcid-ver">PMC12407842.1</article-id><article-id pub-id-type="pmcaid">12407842</article-id><article-id pub-id-type="pmcaiid">12407842</article-id><article-id pub-id-type="pmid">40799045</article-id><article-id pub-id-type="doi">10.1080/14796694.2025.2543673</article-id><article-id pub-id-type="publisher-id">2543673</article-id><article-version-alternatives><article-version article-version-type="pmc-version">1</article-version><article-version vocab="JAV" vocab-identifier="http://www.niso.org/publications/rp/RP-8-2008.pdf" vocab-term="Version of Record" article-version-type="VoR">Version of Record</article-version></article-version-alternatives><article-categories><subj-group subj-group-type="article-type"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>Clinical representativeness of pivotal trials for T-cell engagers in relapsed/refractory follicular lymphoma</article-title><alt-title alt-title-type="left-running-head">Z. DING ET AL.</alt-title><alt-title alt-title-type="right-running-head">FUTURE ONCOLOGY</alt-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Ding</surname><given-names initials="Z">Zhijie</given-names></name><xref rid="aff0001" ref-type="aff">
<sup>a</sup>
</xref><xref rid="an0001" ref-type="corresp"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Zhang</surname><given-names initials="G">Guihua</given-names></name><xref rid="aff0001" ref-type="aff">
<sup>a</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Yu</surname><given-names initials="J">Junhua</given-names></name><xref rid="aff0002" ref-type="aff">
<sup>b</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Wang</surname><given-names initials="T">Tongsheng</given-names></name><xref rid="aff0001" ref-type="aff">
<sup>a</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Kamalakar</surname><given-names initials="R">Rajesh</given-names></name><xref rid="aff0002" ref-type="aff">
<sup>b</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Bains Chawla</surname><given-names initials="S">Savreet</given-names></name><xref rid="aff0001" ref-type="aff">
<sup>a</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Chhibber</surname><given-names initials="A">Anindit</given-names></name><xref rid="aff0001" ref-type="aff">
<sup>a</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Wang</surname><given-names initials="A">Anthony</given-names></name><xref rid="aff0002" ref-type="aff">
<sup>b</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Alshreef</surname><given-names initials="A">Abualbishr</given-names></name><xref rid="aff0002" ref-type="aff">
<sup>b</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Tybor</surname><given-names initials="D">David</given-names></name><xref rid="aff0002" ref-type="aff">
<sup>b</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Marques Goncalves</surname><given-names initials="F">Felipe</given-names></name><xref rid="aff0001" ref-type="aff">
<sup>a</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Rivas Navarro</surname><given-names initials="F">Fernando</given-names></name><xref rid="aff0003" ref-type="aff">
<sup>c</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Atiya</surname><given-names initials="M">Mohammad</given-names></name><xref rid="aff0001" ref-type="aff">
<sup>a</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Favaro</surname><given-names initials="E">Elena</given-names></name><xref rid="aff0003" ref-type="aff">
<sup>c</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Mutebi</surname><given-names initials="A">Alex</given-names></name><xref rid="aff0001" ref-type="aff">
<sup>a</sup>
</xref></contrib><aff id="aff0001"><label>a</label><institution-wrap><institution>Genmab US Inc</institution></institution-wrap>, <city>Plainsboro</city>, <state>NJ</state>, <country>USA</country></aff><aff id="aff0002"><label>b</label><institution-wrap><institution>AbbVie, Inc</institution></institution-wrap>, <city>North Chicago</city>, <state>IL</state>, <country>USA</country></aff><aff id="aff0003"><label>c</label><institution-wrap><institution>Genmab</institution></institution-wrap>, <city>Copenhagen</city>, <country>Denmark</country></aff></contrib-group><author-notes><corresp id="an0001">CONTACT Zhijie Ding <email xlink:href="mailto:zhdi@genmab.com">zhdi@genmab.com</email> Center for Outcomes Research, Real World Evidence and Epidemiology, Genmab US Inc, <addr-line>777 Scudders Mill Road</addr-line>, <city>Plainsboro</city>, <state>NJ</state><postal-code>08536</postal-code></corresp></author-notes><pub-date date-type="pub" publication-format="electronic"><day>13</day><month>8</month><year>2025</year></pub-date><pub-date date-type="collection" publication-format="electronic"><year>2025</year></pub-date><volume>21</volume><issue>21</issue><issue-id pub-id-type="pmc-issue-id">496179</issue-id><fpage seq="11">2795</fpage><lpage>2801</lpage><pub-history><event event-type="pmc-release"><date><day>13</day><month>08</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>04</day><month>09</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-09-04 11:25:27.617"><day>04</day><month>09</month><year>2025</year></date></event><event event-type="tagger"><event-desc>Integra</event-desc><date><day>20</day><month>8</month><year>2025</year></date></event><event event-type="final"><event-desc>Integra</event-desc><date><day>20</day><month>8</month><year>2025</year></date></event><event event-type="received"><date><day>03</day><month>6</month><year>2025</year></date></event><event event-type="accepted"><date><day>01</day><month>8</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>&#169; 2025 Genmab. Published by Informa UK Limited, trading as Taylor &amp; Francis Group.</copyright-statement><copyright-year>2025</copyright-year><copyright-holder>Genmab</copyright-holder><license><ali:license_ref specific-use="textmining" content-type="ccbyncndlicense">https://creativecommons.org/licenses/by-nc-nd/4.0/</ali:license_ref><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">http://creativecommons.org/licenses/by-nc-nd/4.0/</ext-link>), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited, and is not altered, transformed, or built upon in any way. The terms on which this article has been published allow the posting of the Accepted Manuscript in a repository by the author(s) or with their consent.</license-p></license></permissions><self-uri content-type="pmc-pdf" xlink:href="IFON_21_2543673.pdf"/><self-uri content-type="pdf" xlink:href="IFON_21_2543673.pdf"/><abstract><title>ABSTRACT</title><sec><title>Aim</title><p>To characterize trial populations of T-cell&#8211;engaging therapies, including bispecific antibodies and chimeric antigen receptor T-cell therapies, for relapsed/refractory (R/R) follicular lymphoma (FL) after&#8201;&#8805;&#8201;2 systemic therapies and the extent to which they represent real-world R/R FL populations.</p></sec><sec><title>Methods</title><p>Inclusion/exclusion criteria and baseline characteristics were compared descriptively for EPCORE NHL-1 (epcoritamab, N&#8201;=&#8201;128), GO29781 (mosunetuzumab, N&#8201;=&#8201;90), ELARA (tisagenlecleucel [tisa-cel], N&#8201;=&#8201;97), and ZUMA-5 (axicabtagene ciloleucel [axi-cel], N&#8201;=&#8201;124). Real-world data from the COTA Healthcare (New York, NY) and Optum Market Clarity (Eden Prairie, MN) databases contextualized the clinical representativeness of trial populations.</p></sec><sec><title>Results</title><p>The epcoritamab trial enrolled a higher proportion of patients who were older, had higher Follicular Lymphoma International Prognostic Index scores, and were more double-refractory versus other trials. Notably, 37% of epcoritamab trial patients would have been excluded from the mosunetuzumab trial, 30% from the tisa-cel trial, and 29% from the axi-cel trial. These excluded subgroups were characterized by factors associated with poor clinical outcomes.</p></sec><sec><title>Conclusion</title><p>The epcoritamab trial enrolled more broadly and was more representative of typical R/R FL patients than the mosunetuzumab, tisa-cel, and axi-cel trials. Differences in patient characteristics should be considered when evaluating the comparative benefits of T-cell engagers in R/R FL after&#8201;&#8805;&#8201;2 systemic therapies.</p></sec></abstract><abstract abstract-type="plain-language-summary"><title>Plain Language Summary</title><p>A number of therapies have been approved recently for the treatment of relapsed/refractory follicular lymphoma, a type of blood cancer. Epcoritamab, mosunetuzumab, tisagenlecleucel (tisa-cel), and axicabtagene ciloleucel (axi-cel) have demonstrated efficacy in separate key clinical trials. However, it is difficult to know which therapy works better since they have not been compared against each other in the same study. To better understand how the efficacy of these treatments compare, we looked at the types of patients who were included in the clinical trials for epcoritamab, mosunetuzumab, tisa-cel, and axi-cel, asking whether patient populations differed across the different trials. Trials that are more restrictive in their selection of study participants may end up with populations that do not reflect the types of people treated in an everyday practice environment. Therefore, we also looked at real-world patient data to see how similar the patients included in these trials were to patients in real-world clinical practice. Overall, the populations in the 4 trials differed substantially. The epcoritamab trial included a broader, more clinically diverse population compared with the mosunetuzumab, tisa-cel, and axi-cel trials. Notably, 37% of epcoritamab trial patients would have been excluded from the mosunetuzumab trial, 30% from the tisa-cel trial, and 29% from the axi-cel trial. Because of this, the epcoritamab trial (EPCORE NHL-1) may better reflect real-world clinical practice compared with trials of similar therapies, and the results are more generalizable to patients in clinical practice. Differences in the trial populations should be considered when comparing these treatments.</p></abstract><kwd-group kwd-group-type="author"><title>KEYWORDS</title><kwd>Trial eligibility</kwd><kwd>epcoritamab</kwd><kwd>prognostic factors</kwd><kwd>patient population</kwd><kwd>real-world evidence</kwd></kwd-group><support-group><funding-group><award-group><funding-source><institution-wrap><institution>Genmab A/S</institution></institution-wrap></funding-source></award-group><award-group><funding-source><institution-wrap><institution>AbbVie</institution><institution-id institution-id-type="open-funder-registry">10.13039/100006483</institution-id></institution-wrap></funding-source></award-group><funding-statement>Genmab A/S and AbbVie funded this study and participated in the study design, research, analysis, data collection, interpretation of data, reviewing, and approval of this article.</funding-statement></funding-group></support-group><counts><fig-count count="1"/><table-count count="3"/><ref-count count="23"/><page-count count="7"/></counts><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec sec-type="intro" disp-level="1" id="s0001"><label>1.</label><title>Introduction</title><p>Follicular lymphoma (FL), an indolent and incurable disease, is one of the most common types of non-Hodgkin lymphoma (NHL), with approximately 15,000 new cases annually in the United States [<xref rid="cit0001" ref-type="bibr">1</xref>]. Although FL is associated with an overall 5-year survival rate of 89.9%, a substantial proportion of patients experience relapse and become increasingly resistant to treatment; with each subsequent treatment, remissions tend to be shorter [<xref rid="cit0002" ref-type="bibr">2&#8211;6</xref>]. Patients with FL are a heterogeneous population, with some having long periods of remission while others experience cycles of relapse and remission or rapidly progressing disease that can transform into diffuse large B-cell lymphoma [<xref rid="cit0007" ref-type="bibr">7&#8211;9</xref>]. The variability of disease progression directly affects treatment strategies [<xref rid="cit0010" ref-type="bibr">10</xref>]. Although the evolving treatment armamentarium for FL addresses the unmet needs presented by such a wide-ranging clinical course, the clinical heterogeneity of FL presents challenges in the selection of treatment strategies [<xref rid="cit0006" ref-type="bibr">6</xref>].</p><p>T-cell&#8211;engaging therapies, specifically bispecific antibodies and chimeric antigen receptor T-cell (CAR T) therapies, have emerged as compelling treatment options for relapsed/refractory (R/R) FL [<xref rid="cit0011" ref-type="bibr">11&#8211;14</xref>]. Recently approved therapies for R/R FL after&#8201;&#8805;2 systemic therapies include mosunetuzumab, tisagenlecleucel (tisa-cel), axicabtagene ciloleucel (axi-cel), and epcoritamab [<xref rid="cit0015" ref-type="bibr">15&#8211;18</xref>]. Epcoritamab, tisa-cel, and axi-cel are also approved for the treatment of diffuse large B-cell lymphoma [<xref rid="cit0016" ref-type="bibr">16&#8211;18</xref>]. Although single-arm pivotal trials have demonstrated the efficacy of these treatments, they do not provide information on their comparative benefits [<xref rid="cit0019" ref-type="bibr">19</xref>]. Indirect treatment comparisons or more specifically in this case, matching adjusted indirect comparisons, can be used to estimate and compare clinical outcomes from separate trials [<xref rid="cit0020" ref-type="bibr">20</xref>]. For matching adjusted indirect comparisons to be feasible, however, the trial populations need to have similar inclusion and exclusion criteria, the study designs should be generally comparable, and sufficient overlap is required among the patient populations of interest in the trials being compared [<xref rid="cit0021" ref-type="bibr">21</xref>]. Differences in trial populations warrant particular consideration when comparing clinical outcomes among therapies. Clinical trials tend to include a narrow population of patients with stringent eligibility criteria, which limits the generalizability of trial findings [<xref rid="cit0022" ref-type="bibr">22</xref>,<xref rid="cit0023" ref-type="bibr">23</xref>]. Therefore, it is important to understand how closely study populations reflect real-world clinical practice.</p><p>The objective of this analysis was to characterize the differences in patient populations enrolled in the pivotal trials of T-cell&#8211;engaging therapies (ie, epcoritamab, mosunetuzumab, tisa-cel, and axi-cel) in R/R FL after&#8201;&#8805;&#8201;2 systemic therapies. Along with describing differences among the patient populations included in each of the trials, this analysis also assessed the clinical representativeness of these trial populations and explored the impact of potential prognostic factors on clinical outcomes. The clinical representativeness of the trial populations was assessed using electronic health record (EHR) data from US clinical practice sites.</p></sec><sec disp-level="1" id="s0002"><label>2.</label><title>Materials &amp; methods</title><p>The pivotal trials for epcoritamab (EPCORE NHL-1; <ext-link ext-link-type="pmc:clinical-trial" xlink:href="NCT03625037">NCT03625037</ext-link>), mosunetuzumab (GO29781; <ext-link ext-link-type="pmc:clinical-trial" xlink:href="NCT02500407">NCT02500407</ext-link>), tisa-cel (ELARA; <ext-link ext-link-type="pmc:clinical-trial" xlink:href="NCT03568461">NCT03568461</ext-link>), and axi-cel (ZUMA-5; <ext-link ext-link-type="pmc:clinical-trial" xlink:href="NCT03105336">NCT03105336</ext-link>) in patients with R/R FL after&#8201;&#8805;2 lines of therapy (LOTs) were evaluated [<xref rid="cit0011" ref-type="bibr">11&#8211;14</xref>]. The inclusion and exclusion criteria and the baseline demographic and clinical characteristics of the patients enrolled in each of these trials were compared to characterize patient subgroups that may be unique to specific trials, including the presence of characteristics that may be associated with poor prognosis. The characteristics of these trial populations were then compared with real-world patient populations with R/R FL after&#8201;&#8805;2 LOTs in the COTA (COTA Healthcare, New York, NY) and Optum Market Clarity (OMC; Optum, Eden Prairie, MN) databases from US clinical practice to assess the clinical representativeness of these trials. In addition, the real-world patient populations from the COTA and OMC databases were used to examine the association between prognostic factors and clinical outcomes.</p><p>The COTA EHR database is composed of EHRs submitted from academic medical centers and community practice sites in the United States. The COTA EHR database contains patient demographic and clinical information, including diagnostic factors, treatment data, and outcomes data. The abstraction of data by COTA was based on a review of source documentation and de-identified patient data in a manner compliant with the Health Insurance Portability and Accountability Act (HIPAA). For this analysis, patients were selected if they had a diagnosis of FL and subsequent treatment between January 2010 and December 2022 inclusive. Patients diagnosed before 2010 were excluded from this study because EHRs were not mandated prior to that date; thus, a high degree of missing data can be expected before 2010. A diagnosis of FL was based on a record of pathological confirmation of an initial FL diagnosis.</p><p>OMC Dataset combines transactional pharmacy and medical claims data with EHR data. Data are de-identified and statistician-certified, and are fully HIPAA-compliant. The OMC database links EHR data with administrative, pharmacy, physician, and facility claims (with clinical information) and is inclusive of medications prescribed and administered. Specific data elements sourced from EHRs include lab results, vital signs and measurements, diagnoses, procedures, and information derived from unstructured clinical notes using natural language processing. The overall OMC database included 3072 patients with FL who had&#8201;&#8805;2 systemic therapies based on inclusion criteria.</p><p>Kaplan-Meier analyses were conducted using COTA and OMC data to assess the univariate association of overall survival (OS) with certain baseline characteristics (ie, Eastern Cooperative Oncology Group (ECOG) performance status [PS; 0, 1, 2, or 3], estimated glomerular filtration rate [eGFR; mL/min/1.73&#8201;m<sup>2</sup>: &#8805;60, 45&#8211;&lt;60, 30&#8211;&lt;45,&#8201;&lt;30], and baseline hemoglobin &#8804;10&#8201;g/dL [yes/no]) by using each characteristic separately as the stratification variable. The characteristics for the univariate analysis were selected based on their use as trial inclusion/exclusion criteria and their availability in COTA or OMC databases. Due to data availability, additional survival analyses using OMC were conducted for OS stratified by lymphocyte count&#8201;&lt;300&#8201;&#181;L (yes/no), bronchospasm or chronic obstructive pulmonary disease (COPD; yes/no), and pleural effusion (yes/no).</p></sec><sec disp-level="1" id="s0003"><label>3.</label><title>Results</title><p>Overall, the study populations of these pivotal trials differed substantially, with the inclusion criteria of the epcoritamab trial notably less restrictive than that for the mosunetuzumab, tisa-cel, and axi-cel trials. The epcoritamab trial population had more older patients, a higher proportion of Follicular Lymphoma International Prognostic Index scores&#8201;&#8805;&#8201;3, and a greater percentage with double-refractory disease compared with the mosunetuzumab, tisa-cel, and axi-cel trials. The epcoritamab trial included a higher proportion of patients with Ann Arbor stage III/IV involvement than the mosunetuzumab trial (<xref rid="t0001" ref-type="table">Table 1</xref>). Moreover, due to its broader eligibility criteria, the epcoritamab trial enrolled patients who were excluded from the mosunetuzumab, tisa-cel, and axi-cel trials: those with ECOG PS 2, moderate to severe renal dysfunction characterized by creatinine clearance (CrCl)&#8201;&lt;&#8201;60&#8201;mL/min and &#8805;&#8201;45&#8201;mL/min, and hemoglobin levels&#8201;&lt;&#8201;8&#8201;g/dL (<xref rid="t0002 t0003" ref-type="table">Tables 2 and 3</xref>; Supplementary Tables S1, S2, and S3). Specifically, 47 (37%), 38 (30%), and 37 (29%) patients in the epcoritamab trial were ineligible for the mosunetuzumab, tisa-cel, and axi-cel trials, respectively (<xref rid="f0001" ref-type="fig">Figure 1(A-C)</xref>). The most common reasons for patient exclusion in the mosunetuzumab, tisa-cel, and axi-cel trials included an ECOG PS of 2, low hemoglobin, impaired renal function, low oxygen saturation, and prior CAR T therapy (<xref rid="t0003" ref-type="table">Table 3</xref>).
<fig position="float" id="f0001" fig-type="figure" orientation="portrait"><label>Figure 1.</label><caption><p>Proportion of patients in the epcoritamab trial who would have been excluded from the (A) mosunetuzumab, (B) tisagenlecleucel, and (C) axicabtagene ciloleucel trials based on inclusion criteria.</p></caption><alternatives><graphic content-type="color" specific-use="web-only" position="float" orientation="portrait" xlink:href="IFON_A_2543673_F0001_OC.jpg"/><graphic content-type="black-white" specific-use="print-only" position="float" orientation="portrait" xlink:href="IFON_A_2543673_F0001_PB.jpg"/></alternatives></fig><table-wrap position="float" id="t0001" orientation="portrait"><label>Table 1.</label><caption><p>Key patient characteristics and outcomes of EPCORE NHL-1 and comparator trials in relapsed/refractory follicular lymphoma [<xref rid="cit0011" ref-type="bibr">11&#8211;14</xref>].</p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col width="1*" align="left" span="1"/><col width="1*" align="center" span="1"/><col width="1*" align="center" span="1"/><col width="1*" align="center" span="1"/><col width="1*" align="center" span="1"/></colgroup><thead><tr><th align="left" colspan="1" rowspan="1">Characteristics</th><th align="center" colspan="1" rowspan="1">EPCORE NHL-1<break/>Epcoritamab<break/>(N&#8201;=&#8201;128)</th><th align="center" colspan="1" rowspan="1">GO29781<break/>Mosunetuzumab<break/>(N&#8201;=&#8201;90)</th><th align="center" colspan="1" rowspan="1">ELARA<break/>Tisa-cel<break/>(N&#8201;=&#8201;97)</th><th align="center" colspan="1" rowspan="1">ZUMA-5<break/>Axi-cel<break/>(N&#8201;=&#8201;124)</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">Trial design</td><td align="center" colspan="1" rowspan="1">Open label, phase 1/2</td><td align="center" colspan="1" rowspan="1">Open label, phase 2</td><td align="center" colspan="1" rowspan="1">Open label, phase 2</td><td align="center" colspan="1" rowspan="1">Open label, phase 2</td></tr><tr><td align="left" colspan="1" rowspan="1">Comparator in trial</td><td align="center" colspan="1" rowspan="1">No comparator</td><td align="center" colspan="1" rowspan="1">No comparator</td><td align="center" colspan="1" rowspan="1">No comparator</td><td align="center" colspan="1" rowspan="1">No comparator</td></tr><tr><td align="left" colspan="1" rowspan="1">Median age, y</td><td align="center" colspan="1" rowspan="1">65</td><td align="center" colspan="1" rowspan="1">60</td><td align="center" colspan="1" rowspan="1">57</td><td align="center" colspan="1" rowspan="1">60</td></tr><tr><td align="left" colspan="1" rowspan="1">Age &#8805;&#8201;65 y, n (%)</td><td align="center" colspan="1" rowspan="1">67 (52.3)</td><td align="center" colspan="1" rowspan="1">30 (33.3)</td><td align="center" colspan="1" rowspan="1">24 (24.7)</td><td align="center" colspan="1" rowspan="1">38 (30.6)</td></tr><tr><td align="left" colspan="1" rowspan="1">Male, n (%)</td><td align="center" colspan="1" rowspan="1">79 (61.7)</td><td align="center" colspan="1" rowspan="1">55 (61.1)</td><td align="center" colspan="1" rowspan="1">64 (66.0)</td><td align="center" colspan="1" rowspan="1">73 (58.9)</td></tr><tr><td align="left" colspan="1" rowspan="1">ECOG PS 0&#8211;1, n (%)</td><td align="center" colspan="1" rowspan="1">121 (94.5)</td><td align="center" colspan="1" rowspan="1">90 (100)</td><td align="center" colspan="1" rowspan="1">97 (100)</td><td align="center" colspan="1" rowspan="1">124 (100)</td></tr><tr><td align="left" colspan="1" rowspan="1">Median prior LOTs, n (range)</td><td align="center" colspan="1" rowspan="1">3 (2&#8211;9)</td><td align="center" colspan="1" rowspan="1">3 (IQR 2&#8211;4)</td><td align="center" colspan="1" rowspan="1">4 (2&#8211;13)</td><td align="center" colspan="1" rowspan="1">3 (IQR 2&#8211;4)</td></tr><tr><td align="left" colspan="1" rowspan="1">Double refractory, n (%)</td><td align="center" colspan="1" rowspan="1">90 (70.3)</td><td align="center" colspan="1" rowspan="1">48 (53.3)</td><td align="center" colspan="1" rowspan="1">66 (68.0)</td><td align="center" colspan="1" rowspan="1">74 (58.3)</td></tr><tr><td align="left" colspan="1" rowspan="1">FLIPI score&#8201;&#8805;&#8201;3, n (%)</td><td align="center" colspan="1" rowspan="1">78 (60.9)</td><td align="center" colspan="1" rowspan="1">40 (44.4)</td><td align="center" colspan="1" rowspan="1">58 (59.8)</td><td align="center" colspan="1" rowspan="1">54 (43.5)</td></tr><tr><td align="left" colspan="1" rowspan="1">Ann Arbor stage III/IV, n (%)</td><td align="center" colspan="1" rowspan="1">109 (85.2)</td><td align="center" colspan="1" rowspan="1">69 (76.7)</td><td align="center" colspan="1" rowspan="1">83 (85.6)</td><td align="center" colspan="1" rowspan="1">106 (85.4)</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8805;&#8201;3 prior LOTs, n (%)</td><td align="center" colspan="1" rowspan="1">81 (63.3)</td><td align="center" colspan="1" rowspan="1">56 (62.2)</td><td align="center" colspan="1" rowspan="1">&#8211;</td><td align="center" colspan="1" rowspan="1">78 (62.9)</td></tr><tr><td align="left" colspan="1" rowspan="1">Prior ASCT, n (%)</td><td align="center" colspan="1" rowspan="1">24 (18.8)</td><td align="center" colspan="1" rowspan="1">19 (21.1)</td><td align="center" colspan="1" rowspan="1">35 (36.1)</td><td align="center" colspan="1" rowspan="1">30 (24.2)</td></tr><tr><td align="left" colspan="1" rowspan="1">Prior CAR T therapy, n (%)</td><td align="center" colspan="1" rowspan="1">6 (4.7)</td><td align="center" colspan="1" rowspan="1">3 (3.3)</td><td align="center" colspan="1" rowspan="1">0</td><td align="center" colspan="1" rowspan="1">0</td></tr><tr><td align="left" colspan="1" rowspan="1">Refractory to last therapy, n (%)</td><td align="center" colspan="1" rowspan="1">88 (68.8)</td><td align="center" colspan="1" rowspan="1">62 (68.9)</td><td align="center" colspan="1" rowspan="1">76 (78.4)</td><td align="center" colspan="1" rowspan="1">84 (67.7)</td></tr><tr><td align="left" colspan="1" rowspan="1">POD24, n (%)</td><td align="center" colspan="1" rowspan="1">67 (52.3)</td><td align="center" colspan="1" rowspan="1">47 (52.2)</td><td align="center" colspan="1" rowspan="1">61 (62.9)</td><td align="center" colspan="1" rowspan="1">68 (54.8)</td></tr><tr><td colspan="5" align="left" rowspan="1">Response rates reported from the respective trials<sup>a</sup></td></tr><tr><td align="left" colspan="1" rowspan="1">ORR, %</td><td align="center" colspan="1" rowspan="1">82.0</td><td align="center" colspan="1" rowspan="1">80</td><td align="center" colspan="1" rowspan="1">86.2</td><td align="center" colspan="1" rowspan="1">94</td></tr><tr><td align="left" colspan="1" rowspan="1">CR, %</td><td align="center" colspan="1" rowspan="1">62.5</td><td align="center" colspan="1" rowspan="1">60</td><td align="center" colspan="1" rowspan="1">69.1</td><td align="center" colspan="1" rowspan="1">79</td></tr></tbody></table><table-wrap-foot><fn id="tfn0001"><p><sup>a</sup>ORRs and CRs reported in the various trials were based on evaluable patients, which in some cases was different than the total number of patients included in a particular trial. Values are shown as presented in the various trials.</p></fn><fn id="tfn0002"><p>ACST, autologous stem cell transplant; axi-cel, axicabtagene ciloleucel; CAR T, chimeric antigen receptor T cell; CR, complete response; ECOG PS, Eastern Cooperative Oncology Group performance status; FL, follicular lymphoma; FLIPI, Follicular Lymphoma International Prognostic Index; IQR, interquartile range; LOT, line of therapy; ORR, overall response rate; POD24, progression of disease within 24&#8201;months of therapy initiation; R/R, relapsed/refractory; tisa-cel, tisagenlecleucel.</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="t0002" orientation="portrait"><label>Table 2.</label><caption><p>Notable differences in the inclusion/exclusion criteria for EPCORE NHL-1 and comparator trials.</p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col width="1*" align="left" span="1"/><col width="1*" align="center" span="1"/><col width="1*" align="center" span="1"/><col width="1*" align="center" span="1"/><col width="1*" align="center" span="1"/></colgroup><thead><tr><th align="left" colspan="1" rowspan="1">Characteristics</th><th align="center" colspan="1" rowspan="1">EPCORE NHL-1<break/>Epcoritamab<break/>(N&#8201;=&#8201;128)</th><th align="center" colspan="1" rowspan="1">GO29781<break/>Mosunetuzumab<break/>(N&#8201;=&#8201;90)</th><th align="center" colspan="1" rowspan="1">ELARA<break/>Tisa-cel<break/>(N&#8201;=&#8201;97)</th><th align="center" colspan="1" rowspan="1">ZUMA-5<break/>Axi-cel<break/>(N&#8201;=&#8201;124)</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">ECOG PS</td><td align="center" colspan="1" rowspan="1">0&#8211;2</td><td align="center" colspan="1" rowspan="1">0&#8211;1</td><td align="center" colspan="1" rowspan="1">0&#8211;1</td><td align="center" colspan="1" rowspan="1">0&#8211;1</td></tr><tr><td align="left" colspan="1" rowspan="1">Lymphocyte counts</td><td align="center" colspan="1" rowspan="1">&#8201;&lt;&#8201;5&#8201;&#215;&#8201;10<sup>9</sup>/L</td><td align="center" colspan="1" rowspan="1">NA</td><td align="center" colspan="1" rowspan="1">&#8201;&gt;&#8201;300/mm<sup>3</sup>
<break/>(&#8201;&gt;&#8201;0.3&#8201;&#215;&#8201;10<sup>9</sup>/L)</td><td align="center" colspan="1" rowspan="1">&#8805;&#8201;100/&#181;L</td></tr><tr><td align="left" colspan="1" rowspan="1">Total hemoglobin</td><td align="center" colspan="1" rowspan="1">&#160;</td><td align="center" colspan="1" rowspan="1">&#8805;&#8201;10&#8201;g/dL without transfusion within 21&#8201;days prior to first dose of mosunetuzumab</td><td align="center" colspan="1" rowspan="1">&#8805;&#8201;8.0&#8201;g/dL <break/>(&#8805;&#8201;4.9&#8201;mmol/L)</td><td align="center" colspan="1" rowspan="1">NA</td></tr><tr><td align="left" colspan="1" rowspan="1">Creatinine clearance or serum creatinine</td><td align="center" colspan="1" rowspan="1"><italic toggle="yes">Excluded</italic>: Estimated <break/>CrCl&#8201;&lt;&#8201;45&#8201;mL/min</td><td align="center" colspan="1" rowspan="1">Serum creatinine &#8804; ULN or estimated CrCl &#8805; 60&#8201;mL/min</td><td align="center" colspan="1" rowspan="1">Serum creatinine of <break/>&#8804;&#8201;1.5 &#215; ULN or eGFR &#8805;&#8201;60 mL/min/1.73 m<sup>2</sup></td><td align="center" colspan="1" rowspan="1">Creatinine clearance &#8805;&#8201;60&#8201;mL/min</td></tr><tr><td align="left" colspan="1" rowspan="1">Baseline oxygen saturation</td><td align="center" colspan="1" rowspan="1">NR</td><td align="center" colspan="1" rowspan="1">NA</td><td align="center" colspan="1" rowspan="1">&#8201;&gt;&#8201;90%</td><td align="center" colspan="1" rowspan="1">&#8201;&gt;&#8201;92%</td></tr><tr><td align="left" colspan="1" rowspan="1">Ongoingbronchospasm or COPD</td><td align="center" colspan="1" rowspan="1">NR</td><td align="left" colspan="1" rowspan="1"><italic toggle="yes">Excluded</italic>: Significant active pulmonary disease (eg, bronchospasm and/or COPD)</td><td align="center" colspan="1" rowspan="1">NA</td><td align="center" colspan="1" rowspan="1">NA</td></tr><tr><td align="left" colspan="1" rowspan="1">Pleural effusion</td><td align="center" colspan="1" rowspan="1">NR</td><td align="center" colspan="1" rowspan="1">NA</td><td align="center" colspan="1" rowspan="1">NA</td><td align="center" colspan="1" rowspan="1"><italic toggle="yes">Excluded</italic>: Clinically significant pleural effusion</td></tr><tr><td align="left" colspan="1" rowspan="1">Prior CAR T therapy</td><td align="left" colspan="1" rowspan="1">30&#8201;days must pass (from CAR T therapy) prior to first epcoritamab administration</td><td align="left" colspan="1" rowspan="1"><italic toggle="yes">Excluded</italic>: Prior CAR T therapy within 30&#8201;days before first mosunetuzumab administration</td><td align="center" colspan="1" rowspan="1"><italic toggle="yes">Excluded</italic>: Prior anti-CD19 therapy<break/><italic toggle="yes">Excluded</italic>: Prior gene therapy</td><td align="center" colspan="1" rowspan="1"><italic toggle="yes">Excluded</italic>: Prior CD19 targeted therapy, except patients who received axi-cel in this trial and are eligible for retreatment<break/><italic toggle="yes">Excluded</italic>: Prior CAR T therapy or other genetically modified T-cell therapy</td></tr></tbody></table><table-wrap-foot><fn id="tfn0003"><p>Axi-cel, axicabtagene ciloleucel; CAR T, chimeric antigen receptor T cell; COPD, chronic obstructive pulmonary disease; CrCl, creatinine clearance; ECOG PS, Eastern Cooperative Oncology Group performance status; eGFR, estimated glomerular filtration rate; NA, not applicable; NR, no restrictions; tisa-cel, tisagenlecleucel; ULN, upper limit of normal.</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="t0003" orientation="portrait"><label>Table 3.</label><caption><p>Patients enrolled in EPCORE NHL-1 who met exclusion criteria from GO29781, ELARA, and ZUMA-5.</p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col width="1*" align="left" span="1"/><col width="1*" align="char" char="." span="1"/><col width="1*" align="char" char="." span="1"/><col width="1*" align="char" char="." span="1"/></colgroup><thead><tr><th align="left" colspan="1" rowspan="1">Characteristics</th><th align="center" char="." colspan="1" rowspan="1">GO29781<break/>Mosunetuzumab,<break/>n</th><th align="center" char="." colspan="1" rowspan="1">ELARA<break/>Tisa-cel,<break/>n</th><th align="center" char="." colspan="1" rowspan="1">ZUMA-5<break/>Axi-cel,<break/>n</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1"><bold>Total patients in EPCORE NHL-1 excluded from comparator trials</bold><sup><bold>a</bold></sup></td><td align="char" char="." colspan="1" rowspan="1"><bold>47</bold></td><td align="char" char="." colspan="1" rowspan="1"><bold>38</bold></td><td align="char" char="." colspan="1" rowspan="1"><bold>37</bold></td></tr><tr><td align="left" colspan="1" rowspan="1">ECOG PS 2</td><td align="char" char="." colspan="1" rowspan="1">7</td><td align="char" char="." colspan="1" rowspan="1">7</td><td align="char" char="." colspan="1" rowspan="1">7</td></tr><tr><td align="left" colspan="1" rowspan="1">Lymphocyte counts&#8201;&#8804;&#8201;0.3&#8201;&#215;&#8201;10<sup>9</sup>/L</td><td align="char" char="." colspan="1" rowspan="1">0</td><td align="char" char="." colspan="1" rowspan="1">8</td><td align="char" char="." colspan="1" rowspan="1">0</td></tr><tr><td align="left" colspan="1" rowspan="1">Total hemoglobin&#8201;&lt;&#8201;10&#8201;g/dL (mosunetuzumab) or&#8201;&lt;&#8201;8&#8201;g/dL (ELARA)</td><td align="char" char="." colspan="1" rowspan="1">19</td><td align="char" char="." colspan="1" rowspan="1">2</td><td align="char" char="." colspan="1" rowspan="1">0</td></tr><tr><td align="left" colspan="1" rowspan="1">Moderately or severely impaired renal function at baseline (CrCl&#8201;&lt;&#8201;60&#8201;mL/min)</td><td align="char" char="." colspan="1" rowspan="1">22</td><td align="char" char="." colspan="1" rowspan="1">22</td><td align="char" char="." colspan="1" rowspan="1">22</td></tr><tr><td align="left" colspan="1" rowspan="1">Baseline oxygen saturation&#8201;&#8804;&#8201;90% (ELARA) or&#8201;&#8804;&#8201;92% (ZUMA-5)</td><td align="char" char="." colspan="1" rowspan="1">0</td><td align="char" char="." colspan="1" rowspan="1">1</td><td align="char" char="." colspan="1" rowspan="1">2</td></tr><tr><td align="left" colspan="1" rowspan="1">Prior CAR T therapy exposure</td><td align="char" char="." colspan="1" rowspan="1">0</td><td align="char" char="." colspan="1" rowspan="1">6</td><td align="char" char="." colspan="1" rowspan="1">6</td></tr><tr><td align="left" colspan="1" rowspan="1">Ongoing bronchospasm or COPD</td><td align="char" char="." colspan="1" rowspan="1">8</td><td align="char" char="." colspan="1" rowspan="1">0</td><td align="char" char="." colspan="1" rowspan="1">0</td></tr><tr><td align="left" colspan="1" rowspan="1">Pleural effusion</td><td align="char" char="." colspan="1" rowspan="1">0</td><td align="char" char="." colspan="1" rowspan="1">0</td><td align="char" char="." colspan="1" rowspan="1">6</td></tr></tbody></table><table-wrap-foot><fn id="tfn0004"><p><sup>a</sup>Patients could have met&#8201;&#8805;&#8201;1 of the exclusion criteria; therefore, the total number of patients excluded may be less than the sum of the respective columns.</p></fn><fn id="tfn0005"><p>Axi-cel, axicabtagene ciloleucel; CAR T, chimeric antigen receptor T cell; COPD, chronic obstructive pulmonary disease; CrCl, creatinine clearance; ECOG PS, Eastern Cooperative Oncology Group performance status; tisa-cel, tisagenlecleucel.</p></fn></table-wrap-foot></table-wrap></p><p>The mosunetuzumab, tisa-cel, and axi-cel trials excluded patients with ECOG PS of 2 and CrCl&#8201;&lt;&#8201;60&#8201;mL/min, yet the epcoritamab trial included such patients. Two trials (mosunetuzumab and tisa-cel) excluded patients with low hemoglobin levels, low lymphocyte counts (tisa-cel and axi-cel), and low oxygen saturation levels (tisa-cel and axi-cel), while patients with these characteristics were included in the epcoritamab trial (<xref rid="t0003" ref-type="table">Table 3</xref>). The epcoritamab trial had no lower limit on total hemoglobin levels or oxygen saturation and included patients with lymphocyte counts&#8201;&lt;&#8201;5&#8201;&#215;&#8201;10<sup>9</sup>/L (<xref rid="t0002" ref-type="table">Table 2</xref>). Additionally, the mosunetuzumab trial excluded patients with ongoing bronchospasm or COPD, and the axi-cel trial excluded those with pleural effusion. The epcoritamab trial included patients with ongoing bronchospasm, COPD, or pleural effusion. The mosunetuzumab trial had no restrictions on lymphocyte counts, oxygen saturation levels, or pleural effusion. The tisa-cel trial had no restrictions on ongoing bronchospasm, COPD, or pleural effusion. The axi-cel trial had no restrictions on hemoglobin levels, ongoing bronchospasm, or COPD.</p><p>Although the epcoritamab trial had a higher representation of patients with poor prognostic factors compared with the mosunetuzumab, tisa-cel, and axi-cel trials, the unadjusted overall response rates and complete response rates for all 4 trials were generally comparable (<xref rid="t0001" ref-type="table">Table 1</xref>).</p><sec disp-level="2" id="s0003-s2001"><label>3.1.</label><title>Comparison to real-world databases</title><p>Of the inclusion and exclusion criteria evaluated in the 4 trials, the following were available in the COTA EHR database: ECOG PS, total hemoglobin, CrCl or serum clearance, and ongoing bronchospasm or COPD. The overall COTA EHR database included an estimated 3724 adult patients with FL with a treatment record and a first diagnosis from January 1978 to December 2021. A total of 642 patients in the COTA database with R/R FL after&#8201;&#8805;&#8201;2 LOTs were included in the analysis.</p><p>The COTA real-world population of patients with FL reflected broader characteristics than those represented in the mosunetuzumab, tisa-cel, and axi-cel trials. Most patients in the COTA database would have met the more restrictive criteria of the comparator trials (ie, an ECOG PS of 0 or 1, hemoglobin level &#8805;8&#8201;g/dL, eGFR category of &#8805;60&#8201;mL/min, no COPD, and no prior CAR T therapy) (Supplementary Table S4). A notable proportion of patients in the COTA database also met the broader criteria used in the epcoritamab trial but would have been excluded from the mosunetuzumab, tisa-cel, and axi-cel trials; for example, 4.7% had an ECOG PS of&#8201;&#8805;&#8201;2, 6.4% had a hemoglobin level&#8201;&lt;10&#8201;g/dL, and 10.7% had an eGFR category of 45&#8211;60&#8201;mL/min.</p><p>The COTA real-world data also suggested that patients with FL with certain baseline characteristics considered poor prognostic factors (ie, higher ECOG PS, lower eGFR, and baseline hemoglobin &#8804;10&#8201;g/dL), who were included in the epcoritamab trial but largely excluded from the mosunetuzumab, tisa-cel, and axi-cel trials, had reduced OS compared with patients without these factors (Supplementary Figures S1(A&#8211;C)).</p><p>The findings from the analyses of the COTA and OMC databases were consistent. The trial inclusion and exclusion criteria reported in the OMC database were ECOG PS, lymphocyte counts, hemoglobin level, CrCl, eGFR, ongoing bronchospasm or COPD, pleural effusion, and prior CAR T therapy (Supplementary Table S5). Although conclusions could not be drawn due to a high level of missing data, overall trends were observed to support the findings from the COTA database as well as potential associations between bronchospasm or COPD, pleural effusion, and lower OS (Supplementary Figures S2(A&#8211;F)).</p></sec></sec><sec disp-level="1" id="s0004"><label>4.</label><title>Discussion</title><p>The epcoritamab trial, with its broader inclusion criteria, enrolled patients with certain prognostic factors who are typically excluded from clinical trials, including the key trials of mosunetuzumab, tisa-cel, and axi-cel. Whereas the mosunetuzumab, tisa-cel, and axi-cel trials excluded patients with ECOG PS of 2, low hemoglobin, impaired renal function, low oxygen saturation, and prior CAR T therapy, these patients were included in the epcoritamab trial and were also observed in the real-world COTA EHR and OMC databases. Therefore, the epcoritamab trial demonstrated evidence of the therapeutic benefits of epcoritamab for a broader and diverse patient population with R/R FL with disease and baseline characteristics more similar to patients in real clinical practice than patients receiving the other T-cell engagers. The efficacy demonstrated in the epcoritamab trial may be more representative of what could be expected in real-world patients than the results produced from the trials with more restrictive inclusion criteria. The comparable efficacy shown in the epcoritamab trial compared with the mosunetuzumab, tisa-cel, and axi-cel trials despite enrolling higher-risk patients reinforces the potential robustness of the efficacy of epcoritamab across a harder-to-treat population.</p><p>The differences in baseline characteristics, particularly the inclusion of patients with poor prognostic factors in the epcoritamab trial, may have influenced overall response rate and complete response rate outcomes. While unadjusted response rates were generally comparable, the heterogeneity in baseline characteristics should be considered when interpreting results, as it may affect the comparability across trials. Methodologies, such as matching-adjusted indirect comparisons, that adjust for differences in patient baseline characteristics can be used to contextualize data across trials. The populations represented in the mosunetuzumab, tisa-cel, and axi-cel trials were shown to represent up to 63%, 70%, and 71%, respectively, of the patient population represented in the epcoritamab trial. The pivotal trials of mosunetuzumab, tisa-cel, and axi-cel generally excluded patient populations with poor prognostic characteristics. The COTA and OMC real-world data analyses suggested identified as poor prognostic factors have lower OS, and that a notable proportion of patients with FL have several of these factors. Interestingly, the epcoritamab trial with its more clinically heterogeneous population, and inclusion of higher proportions of patients with poor prognostic factors, had unadjusted overall response rates and unadjusted complete response rates that were generally comparable to the other 3 trials despite their more restrictive inclusion criteria.</p><sec disp-level="2" id="s0004-s2001"><label>4.1.</label><title>Strengths and limitations</title><p>In the increasingly outcomes-driven and value-based oncology environment, this analysis reinforces epcoritamab as an efficacious treatment for a broad population. However, the analysis had several limitations. It was descriptive, reporting clinical characteristics and prognostic factors that were used to characterize the trial populations. Differences in the distributions of unmeasured or unknown factors that could also affect the prognosis cannot be ruled out. Notwithstanding these limitations, the analysis included the evidence from the pivotal trials for epcoritamab, mosunetuzumab, tisa-cel, and axi-cel, which consistently measured and reported important and relevant clinical characteristics and prognostic factors in patients with R/R FL after&#8201;&#8805;&#8201;2 systemic therapies. The real-world databases used in the analysis represent clinical practice in both academic and community settings, and the findings from COTA are consistent with those from OMC.</p></sec></sec><sec disp-level="1" id="s0005"><label>5.</label><title>Conclusions</title><p>The epcoritamab pivotal trial, with its less restrictive eligibility criteria, included higher proportions of patients with factors that would have excluded them from the pivotal trials of mosunetuzumab, tisa-cel, and axi-cel. The differences in these trial populations should be considered when evaluating the comparative benefits of these T-cell engagers in R/R FL after&#8201;&#8805;&#8201;2 systemic therapies. By including a broader population in clinical trials, epcoritamab demonstrated efficacy in patients who more closely reflect those seen in real-world clinical practice.</p></sec><sec sec-type="supplementary-material"><title>Supplementary Material</title><supplementary-material id="SM2688" position="float" content-type="local-data" orientation="portrait"><caption><title>Supplemental Material</title></caption><media xlink:href="IFON_A_2543673_SM2688.docx" position="float" orientation="portrait"/></supplementary-material></sec></body><back><sec disp-level="1" id="s0006"><title>Article highlights</title><p>
<list list-type="bullet" id="list_0001"><list-item><p>This analysis described differences in the patient populations included in the pivotal trials for recently approved therapies for relapsed/refractory follicular lymphoma after&#8201;&#8805;&#8201;2 systemic therapies (epcoritamab, mosunetuzumab, tisagenlecleucel [tisa-cel], and axicabtagene ciloleucel [axi-cel]).</p></list-item><list-item><p>Overall, the populations differed substantially. The epcoritamab trial included a more clinically diverse population with characteristics generally excluded in the mosunetuzumab, tisa-cel, and axi-cel trials and associated with poor clinical outcomes.</p></list-item><list-item><p>The broader inclusion and exclusion criteria in the epcoritamab trial (EPCORE NHL-1) is more representative of real-world clinical practice compared with other T-cell engagers.</p></list-item><list-item><p>The differences in these trial populations should be considered when evaluating the comparative benefits of these therapies.</p></list-item><list-item><p>By including a broader population in clinical trials, epcoritamab demonstrated efficacy in patients who more closely reflect those seen in real-world clinical practice.</p></list-item></list></p></sec><sec disp-level="1" id="s0007"><title>Author contributions</title><p><bold>Conceptualization:</bold> Zhijie Ding, Savreet Bains Chawla, Anthony Wang, Felipe Marques Goncalves, Fernando Rivas Navarro, Mohammad Atiya, Elena Favaro, Alex Mutebi</p><p><bold>Data curation:</bold> Zhijie Ding, Guihua Zhang, Junhua Yu, Tongsheng Wang, Rajesh Kamalakar, Savreet Bains Chawla, Anindit Chhibber, Anthony Wang, Abualbishr Alshreef, David Tybor, Felipe Marques Goncalves, Fernando Rivas Navarro, Mohammad Atiya, Elena Favaro, Alex Mutebi</p><p><bold>Formal analysis:</bold> Guihua Zhang, Junhua Yu, Tongsheng Wang, Rajesh Kamalakar</p><p><bold>Funding acquisition:</bold> Zhijie Ding, Guihua Zhang, Junhua Yu, Tongsheng Wang, Rajesh Kamalakar, Savreet Bains Chawla, Anindit Chhibber, Anthony Wang, Abualbishr Alshreef, David Tybor, Felipe Marques Goncalves, Fernando Rivas Navarro, Mohammad Atiya, Elena Favaro, Alex Mutebi</p><p><bold>Investigation:</bold> Zhijie Ding, Guihua Zhang, Junhua Yu, Tongsheng Wang, Rajesh Kamalakar, Savreet Bains Chawla, Anindit Chhibber, Anthony Wang, Abualbishr Alshreef, David Tybor, Felipe Marques Goncalves, Fernando Rivas Navarro, Mohammad Atiya, Elena Favaro, Alex Mutebi</p><p><bold>Methodology:</bold> Zhijie Ding, Guihua Zhang, Junhua Yu, Tongsheng Wang, Rajesh Kamalakar, Savreet Bains Chawla, Anindit Chhibber, Anthony Wang, Abualbishr Alshreef, David Tybor, Felipe Marques Goncalves, Fernando Rivas Navarro, Mohammad Atiya, Elena Favaro, Alex Mutebi</p><p><bold>Project administration:</bold> Zhijie Ding, Guihua Zhang, Junhua Yu, Tongsheng Wang, Rajesh Kamalakar, Savreet Bains Chawla, Anindit Chhibber, Anthony Wang, Abualbishr Alshreef, David Tybor, Felipe Marques Goncalves, Fernando Rivas Navarro, Mohammad Atiya, Elena Favaro, Alex Mutebi</p><p><bold>Resources:</bold> Zhijie Ding, Guihua Zhang, Junhua Yu, Tongsheng Wang, Rajesh Kamalakar, Savreet Bains Chawla, Anindit Chhibber, Anthony Wang, Abualbishr Alshreef, David Tybor, Felipe Marques Goncalves, Fernando Rivas Navarro, Mohammad Atiya, Elena Favaro, Alex Mutebi</p><p><bold>Software:</bold> Zhijie Ding, Guihua Zhang, Junhua Yu, Tongsheng Wang, Rajesh Kamalakar, Savreet Bains Chawla, Anindit Chhibber, Anthony Wang, Abualbishr Alshreef, David Tybor, Felipe Marques Goncalves, Fernando Rivas Navarro, Mohammad Atiya, Elena Favaro, Alex Mutebi</p><p><bold>Supervision:</bold> Zhijie Ding, Alex Mutebi</p><p><bold>Validation:</bold> Zhijie Ding, Guihua Zhang, Junhua Yu, Tongsheng Wang, Rajesh Kamalakar, Savreet Bains Chawla, Anindit Chhibber, Anthony Wang, Abualbishr Alshreef, David Tybor, Felipe Marques Goncalves, Fernando Rivas Navarro, Mohammad Atiya, Elena Favaro, Alex Mutebi</p><p><bold>Visualization:</bold> Junhua Yu, Rajesh Kamalakar</p><p><bold>Roles/Writing - original draft:</bold> Zhijie Ding, Felipe Marques Goncalves, Alex Mutebi</p><p><bold>Writing - review &amp; editing:</bold> Zhijie Ding, Guihua Zhang, Junhua Yu, Tongsheng Wang, Rajesh Kamalakar, Savreet Bains Chawla, Anindit Chhibber, Anthony Wang, Abualbishr Alshreef, David Tybor, Felipe Marques Goncalves, Fernando Rivas Navarro, Mohammad Atiya, Elena Favaro, Alex Mutebi</p></sec><sec sec-type="COI-statement" disp-level="1" id="s0008"><title>Disclosure statement</title><p>Z Ding, G Zhang, T Wang, S Bains Chawla, F Marques Goncalves, F Rivas Navarro, M Atiya, E Favaro, and A Mutebi: Employees and stockholders of Genmab.</p><p>A Chhibber: Employee of Genmab at the time of this analysis.</p><p>J Yu, R Kamalakar, A Wang, A Alshreef, and D Tybor: Employees and stockholders of AbbVie.</p><p>The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.</p><p>Writing and editorial support was provided by Peloton Advantage, LLC, an OPEN Health company, and funded by Genmab.</p></sec><sec disp-level="1" id="s0009"><title>Reviewer disclosures</title><p>Peer reviewers on this manuscript have no relevant financial or other relationships to disclose.</p></sec><sec disp-level="1" id="s0010"><title>Ethical declaration</title><p>This research was conducted in accordance with the principles of the Declaration of Helsinki and the applicable Health Insurance Portability and Accountability Act. Institutional Review Board approval was not required, as the study involved retrospective analysis of de-identified data with no patient intervention or identifiable information.</p></sec><sec sec-type="data-availability" disp-level="1" id="s0011"><title>Data availability statement</title><p>De-identified individual participant data collected during the trial will not be available upon request for further analyses by external independent researchers. Aggregated clinical trial data from the trial is provided via publicly accessible study registries/databases as required by law. For more information, please contact ClinicalTrials@genmab.com.</p></sec><sec sec-type="supplementary-material" disp-level="1" id="s0012"><title>Supplementary material</title><p>Supplemental data for this article can be accessed online at <ext-link xlink:href="https://doi.org/10.1080/14796694.2025.2543673" ext-link-type="uri">https://doi.org/10.1080/14796694.2025.2543673</ext-link></p></sec><ref-list><title>References</title><p>
<bold>Papers of special note have been highlighted as either of interest (&#8226;) or of considerable interest (&#8226;&#8226;) to readers.</bold>
</p><ref id="cit0001"><label>1.</label><mixed-citation publication-type="webpage"><article-title>Follicular lymphoma (FL): leukemia &amp; lymphoma society</article-title>. <year>2025</year><month>Mar</month><day>11</day>. <comment>Available from:</comment><ext-link xlink:href="https://www.lls.org/research/follicular-lymphoma-fl" ext-link-type="uri">https://www.lls.org/research/follicular-lymphoma-fl</ext-link></mixed-citation></ref><ref id="cit0002"><label>2.</label><mixed-citation publication-type="book"><article-title>Cancer stat facts: NHL &#8212; follicular lymphoma</article-title>. <publisher-loc>Bethesda (MD)</publisher-loc>: <publisher-name>National Cancer Institute</publisher-name>; <year>2025</year><month>Mar</month><day>11</day>. <comment>Available from:</comment><ext-link xlink:href="https://seer.cancer.gov/statfacts/html/follicular.html" ext-link-type="uri">https://seer.cancer.gov/statfacts/html/follicular.html</ext-link></mixed-citation></ref><ref id="cit0003"><label>3.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Salles</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Schuster</surname><given-names>SJ</given-names></string-name>, <string-name name-style="western"><surname>Fischer</surname><given-names>L</given-names></string-name>, et al</person-group>. <article-title>A retrospective cohort study of treatment outcomes of adult patients with relapsed or refractory follicular lymphoma (ReCORD-FL)</article-title>. <source>Hemasphere</source>. <year>2022</year>;<volume>6</volume>:<fpage>e745</fpage>. doi: <pub-id pub-id-type="doi">10.1097/HS9.0000000000000745</pub-id><pub-id pub-id-type="pmid">35813099</pub-id><pub-id pub-id-type="pmcid">PMC9263496</pub-id></mixed-citation></ref><ref id="cit0004"><label>4.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Montoto</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>L&#243;pez-Guillermo</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Ferrer</surname><given-names>A</given-names></string-name>, et al</person-group>. <article-title>Survival after progression in patients with follicular lymphoma: analysis of prognostic factors</article-title>. <source>Ann Oncol</source>. <year>2002</year>;<volume>13</volume>(<issue>4</issue>):<fpage>523</fpage>&#8211;<lpage>530</lpage>. doi: <pub-id pub-id-type="doi">10.1093/annonc/mdf119</pub-id><pub-id pub-id-type="pmid">12056701</pub-id></mixed-citation></ref><ref id="cit0005"><label>5.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Ghione</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Palomba</surname><given-names>ML</given-names></string-name>, <string-name name-style="western"><surname>Ghesquieres</surname><given-names>H</given-names></string-name>, et al</person-group>. <article-title>Treatment patterns and outcomes in relapsed/refractory follicular lymphoma: results from the international SCHOLAR-5 study</article-title>. <source>Haematologica</source>. <year>2023</year>;<volume>108</volume>(<issue>3</issue>):<fpage>822</fpage>&#8211;<lpage>832</lpage>. doi: <pub-id pub-id-type="doi">10.3324/haematol.2022.281421</pub-id><pub-id pub-id-type="pmid">36263843</pub-id><pub-id pub-id-type="pmcid">PMC9973479</pub-id></mixed-citation></ref><ref id="cit0006"><label>6.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Zinzani</surname><given-names>PL</given-names></string-name>, <string-name name-style="western"><surname>Mu&#241;oz</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Trotman</surname><given-names>J.</given-names></string-name></person-group><article-title>Current and future therapies for follicular lymphoma</article-title>. <source>Exp Hematol Oncol</source>. <year>2024</year>;<volume>13</volume>:<fpage>87</fpage>. doi: <pub-id pub-id-type="doi">10.1186/s40164-024-00551-1</pub-id><pub-id pub-id-type="pmid">39175100</pub-id><pub-id pub-id-type="pmcid">PMC11340193</pub-id></mixed-citation></ref><ref id="cit0007"><label>7.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Jurinovic</surname><given-names>V</given-names></string-name>, <string-name name-style="western"><surname>Kridel</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Staiger</surname><given-names>AM</given-names></string-name>, et al</person-group>. <article-title>Clinicogenetic risk models predict early progression of follicular lymphoma after first-line immunochemotherapy</article-title>. <source>Blood</source>. <year>2016</year>;<volume>128</volume>:<fpage>1112</fpage>&#8211;<lpage>1120</lpage>. doi: <pub-id pub-id-type="doi">10.1182/blood-2016-05-717355</pub-id><pub-id pub-id-type="pmid">27418643</pub-id><pub-id pub-id-type="pmcid">PMC5457130</pub-id></mixed-citation></ref><ref id="cit0008"><label>8.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Casulo</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Byrtek</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Dawson</surname><given-names>KL</given-names></string-name>, et al</person-group>. <article-title>Early relapse of follicular lymphoma after rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone defines patients at high risk for death: an analysis from the national LymphoCare study</article-title>. <source>J Clin Oncol</source>. <year>2015</year>;<volume>33</volume>(<issue>23</issue>):<fpage>2516</fpage>&#8211;<lpage>2522</lpage>. doi: <pub-id pub-id-type="doi">10.1200/JCO.2014.59.7534</pub-id><pub-id pub-id-type="pmid">26124482</pub-id><pub-id pub-id-type="pmcid">PMC4879714</pub-id></mixed-citation></ref><ref id="cit0009"><label>9.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Wagner-Johnston</surname><given-names>ND</given-names></string-name>, <string-name name-style="western"><surname>Link</surname><given-names>BK</given-names></string-name>, <string-name name-style="western"><surname>Byrtek</surname><given-names>M</given-names></string-name>, et al</person-group>. <article-title>Outcomes of transformed follicular lymphoma in the modern era: a report from the national LymphoCare study (NLCS)</article-title>. <source>Blood</source>. <year>2015</year>;<volume>126</volume>:<fpage>851</fpage>&#8211;<lpage>857</lpage>. doi: <pub-id pub-id-type="doi">10.1182/blood-2015-01-621375</pub-id><pub-id pub-id-type="pmid">26105149</pub-id><pub-id pub-id-type="pmcid">PMC4543911</pub-id></mixed-citation></ref><ref id="cit0010"><label>10.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Matasar</surname><given-names>MJ</given-names></string-name>, <string-name name-style="western"><surname>Luminari</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Barr</surname><given-names>PM</given-names></string-name>, et al</person-group>. <article-title>Follicular lymphoma: recent and emerging therapies, treatment strategies, and remaining unmet needs</article-title>. <source>Oncologist</source>. <year>2019</year>;<volume>24</volume>(<issue>11</issue>):<fpage>e1236</fpage>&#8211;<lpage>e1250</lpage>. doi: <pub-id pub-id-type="doi">10.1634/theoncologist.2019-0138</pub-id><pub-id pub-id-type="pmid">31346132</pub-id><pub-id pub-id-type="pmcid">PMC6853118</pub-id></mixed-citation></ref><ref id="cit0011"><label>11.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Budde</surname><given-names>LE</given-names></string-name>, <string-name name-style="western"><surname>Sehn</surname><given-names>LH</given-names></string-name>, <string-name name-style="western"><surname>Matasar</surname><given-names>M</given-names></string-name>, et al</person-group>. <article-title>Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 study</article-title>. <source>Lancet Oncol</source>. <year>2022</year>;<volume>23</volume>(<issue>8</issue>):<fpage>1055</fpage>&#8211;<lpage>1065</lpage>. doi: <pub-id pub-id-type="doi">10.1016/S1470-2045(22)00335-7</pub-id><pub-id pub-id-type="pmid">35803286</pub-id></mixed-citation><note><p>
<bold>&#8226; of interest.</bold>
</p></note></ref><ref id="cit0012"><label>12.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Fowler</surname><given-names>NH</given-names></string-name>, <string-name name-style="western"><surname>Dickinson</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Dreyling</surname><given-names>M</given-names></string-name>, et al</person-group>. <article-title>Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial</article-title>. <source>Nat Med</source>. <year>2022</year>;<volume>28</volume>:<fpage>325</fpage>&#8211;<lpage>332</lpage>. doi: <pub-id pub-id-type="doi">10.1038/s41591-021-01622-0</pub-id><pub-id pub-id-type="pmid">34921238</pub-id></mixed-citation><note><p>
<bold>&#8226; of interest.</bold>
</p></note></ref><ref id="cit0013"><label>13.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Jacobson</surname><given-names>CA</given-names></string-name>, <string-name name-style="western"><surname>Chavez</surname><given-names>JC</given-names></string-name>, <string-name name-style="western"><surname>Sehgal</surname><given-names>AR</given-names></string-name>, et al</person-group>. <article-title>Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial</article-title>. <source>Lancet Oncol</source>. <year>2022</year>;<volume>23</volume>(<issue>1</issue>):<fpage>91</fpage>&#8211;<lpage>103</lpage>. doi: <pub-id pub-id-type="doi">10.1016/S1470-2045(21)00591-X</pub-id><pub-id pub-id-type="pmid">34895487</pub-id></mixed-citation><note><p>
<bold>&#8226; of interest.</bold>
</p></note></ref><ref id="cit0014"><label>14.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Linton</surname><given-names>KM</given-names></string-name>, <string-name name-style="western"><surname>Vitolo</surname><given-names>U</given-names></string-name>, <string-name name-style="western"><surname>Jurczak</surname><given-names>W</given-names></string-name>, et al</person-group>. <article-title>Epcoritamab monotherapy in patients with relapsed or refractory follicular lymphoma (EPCORE NHL-1): a phase 2 cohort of a single-arm, multicentre study</article-title>. <source>Lancet Haematol</source>. <year>2024</year>;<volume>11</volume>(<issue>8</issue>):<fpage>e593</fpage>&#8211;<lpage>e605</lpage>. doi: <pub-id pub-id-type="doi">10.1016/S2352-3026(24)00166-2</pub-id><pub-id pub-id-type="pmid">38889737</pub-id></mixed-citation><note><p>
<bold>&#8226;&#8226; of considerable interest.</bold>
</p></note></ref><ref id="cit0015"><label>15.</label><mixed-citation publication-type="book"><source>Genentech, Inc. Lunsumio [package insert]</source>. <publisher-loc>South San Francisco (CA), USA</publisher-loc>: <publisher-name>Genentech, Inc</publisher-name>.; <year>2024</year>.</mixed-citation></ref><ref id="cit0016"><label>16.</label><mixed-citation publication-type="book"><source>Genmab US, Inc. Epkinly [package insert]</source>. <publisher-loc>Plainsboro (NJ), USA</publisher-loc>: <publisher-name>Genmab US, Inc</publisher-name>.; <year>2024</year>.</mixed-citation></ref><ref id="cit0017"><label>17.</label><mixed-citation publication-type="book"><source>Novartis Pharmaceuticals Corporation. Kymriah [package insert]</source>. <publisher-loc>East Hanover (NJ)</publisher-loc>: <publisher-name>Novartis Pharmaceuticals Corporation</publisher-name>; <year>2024</year>.</mixed-citation></ref><ref id="cit0018"><label>18.</label><mixed-citation publication-type="book"><source>Kite Pharma. Yescarta [package insert]</source>. <publisher-loc>Santa Monica (CA)</publisher-loc>: <publisher-name>Kite Pharma</publisher-name>; <year>2024</year>.</mixed-citation></ref><ref id="cit0019"><label>19.</label><mixed-citation publication-type="newspaper"><person-group person-group-type="author"><collab>European Medicines Agency</collab></person-group>. <article-title>Reflection paper on establishing efficacy based on single-arm trials submitted as pivotal evidence in a marketing authorisation application. Considerations on evidence from single-arm trials</article-title>. <year>2024</year><month>Jan</month><day>28</day>. <comment>Available from:</comment><ext-link xlink:href="https://www.ema.europa.eu/en/documents/scientific-guideline/reflection-paper-establishing-efficacy-based-single-arm-trials-submitted-pivotal-evidence-marketing-authorisation-application_en.pdf" ext-link-type="uri">https://www.ema.europa.eu/en/documents/scientific-guideline/reflection-paper-establishing-efficacy-based-single-arm-trials-submitted-pivotal-evidence-marketing-authorisation-application_en.pdf</ext-link></mixed-citation></ref><ref id="cit0020"><label>20.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Signorovitch</surname><given-names>JE</given-names></string-name>, <string-name name-style="western"><surname>Sikirica</surname><given-names>V</given-names></string-name>, <string-name name-style="western"><surname>Erder</surname><given-names>MH</given-names></string-name>, et al</person-group>. <article-title>Matching-adjusted indirect comparisons: a new tool for timely comparative effectiveness research</article-title>. <source>Value Health</source>. <year>2012</year>;<volume>15</volume>(<issue>6</issue>):<fpage>940</fpage>&#8211;<lpage>947</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.jval.2012.05.004</pub-id><pub-id pub-id-type="pmid">22999145</pub-id></mixed-citation></ref><ref id="cit0021"><label>21.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Signorovitch</surname><given-names>JE</given-names></string-name>, <string-name name-style="western"><surname>Wu</surname><given-names>EQ</given-names></string-name>, <string-name name-style="western"><surname>Yu</surname><given-names>AP</given-names></string-name>, et al</person-group>. <article-title>Comparative effectiveness without head-to-head trials: a method for matching-adjusted indirect comparisons applied to psoriasis treatment with adalimumab or etanercept</article-title>. <source>Pharmacoeconomics</source>. <year>2010</year>;<volume>28</volume>:<fpage>935</fpage>&#8211;<lpage>945</lpage>. doi: <pub-id pub-id-type="doi">10.2165/11538370-000000000-00000</pub-id><pub-id pub-id-type="pmid">20831302</pub-id></mixed-citation></ref><ref id="cit0022"><label>22.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Heirali</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Heybati</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Sereeyotin</surname><given-names>J</given-names></string-name>, et al</person-group>. <article-title>Eligibility criteria of randomized clinical trials in critical care medicine</article-title>. <source>JAMA Netw Open</source>. <year>2025</year>;<volume>8</volume>:<fpage>e2454944</fpage>. doi: <pub-id pub-id-type="doi">10.1001/jamanetworkopen.2024.54944</pub-id><pub-id pub-id-type="pmid">39821399</pub-id><pub-id pub-id-type="pmcid">PMC11742542</pub-id></mixed-citation></ref><ref id="cit0023"><label>23.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Jin</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Pazdur</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Sridhara</surname><given-names>R</given-names></string-name></person-group>. <article-title>Re-evaluating eligibility criteria for oncology clinical trials: analysis of investigational New drug applications in 2015</article-title>. <source>J Clin Oncol</source>. <year>2017</year>;<volume>35</volume>(<issue>33</issue>):<fpage>3745</fpage>&#8211;<lpage>3752</lpage>. doi: <pub-id pub-id-type="doi">10.1200/JCO.2017.73.4186</pub-id><pub-id pub-id-type="pmid">28968168</pub-id><pub-id pub-id-type="pmcid">PMC5692723</pub-id></mixed-citation></ref></ref-list></back></article>
        
    </metadata>
</record>
    </GetRecord>

</OAI-PMH>